Research Analysts Offer Predictions for BMRN FY2026 Earnings

Key Points

• Cantor Fitzgerald analysts have raised their FY2026 earnings per share estimate for BioMarin Pharmaceutical from $4.29 to $4.84, significantly above the current consensus estimate of $3.15.
• Multiple research firms have varying price targets for BioMarin shares, with Wolfe Research setting a target of $95.00, while Goldman Sachs decreased theirs from $124.00 to $104.00.
• BioMarin Pharmaceutical has a market capitalization of $11.50 billion and a consensus rating of "Moderate Buy" from analysts, with 98.71% of its stock owned by institutional investors.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities research analysts at Cantor Fitzgerald upped their FY2026 earnings per share estimates for BioMarin Pharmaceutical in a note issued to investors on Tuesday, August 5th. Cantor Fitzgerald analyst O. Brayer now forecasts that the biotechnology company will earn $4.84 per share for the year, up from their previous estimate of $4.29. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share.

Several other equities analysts have also issued reports on BMRN. Wolfe Research set a $95.00 price target on BioMarin Pharmaceutical and gave the company an "outperform" rating in a research note on Tuesday, July 15th. The Goldman Sachs Group cut their price target on shares of BioMarin Pharmaceutical from $124.00 to $104.00 and set a "buy" rating on the stock in a research report on Monday, May 5th. Wedbush reiterated an "outperform" rating and issued a $94.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday. JPMorgan Chase & Co. lifted their price target on shares of BioMarin Pharmaceutical from $108.00 to $113.00 and gave the company an "overweight" rating in a research report on Monday, July 14th. Finally, Guggenheim raised their price target on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a "buy" rating in a research report on Wednesday. Six investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $93.17.

BioMarin Pharmaceutical Trading Down 1.2%

BMRN stock opened at $59.96 on Thursday. BioMarin Pharmaceutical has a 52 week low of $52.93 and a 52 week high of $94.85. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.49 and a current ratio of 5.56. The company's 50-day simple moving average is $57.24 and its 200 day simple moving average is $61.79. The company has a market capitalization of $11.50 billion, a PE ratio of 17.77, a price-to-earnings-growth ratio of 0.85 and a beta of 0.18.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Large investors have recently added to or reduced their stakes in the stock. Byrne Financial Freedom LLC increased its position in BioMarin Pharmaceutical by 4.4% during the 1st quarter. Byrne Financial Freedom LLC now owns 3,852 shares of the biotechnology company's stock worth $272,000 after purchasing an additional 161 shares during the period. Freedom Investment Management Inc. boosted its position in shares of BioMarin Pharmaceutical by 3.8% in the fourth quarter. Freedom Investment Management Inc. now owns 5,022 shares of the biotechnology company's stock worth $330,000 after buying an additional 184 shares during the period. Tokio Marine Asset Management Co. Ltd. boosted its holdings in BioMarin Pharmaceutical by 0.9% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 22,523 shares of the biotechnology company's stock valued at $1,592,000 after purchasing an additional 197 shares during the last quarter. Securian Asset Management Inc. increased its holdings in BioMarin Pharmaceutical by 1.4% in the second quarter. Securian Asset Management Inc. now owns 14,604 shares of the biotechnology company's stock valued at $803,000 after buying an additional 197 shares during the last quarter. Finally, Xponance Inc. increased its position in BioMarin Pharmaceutical by 0.6% in the first quarter. Xponance Inc. now owns 31,877 shares of the biotechnology company's stock worth $2,253,000 after buying an additional 202 shares during the period. 98.71% of the stock is owned by institutional investors.

Insider Activity at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,786 shares of the stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total transaction of $105,927.66. Following the completion of the transaction, the chief accounting officer owned 14,173 shares in the company, valued at $840,600.63. This trade represents a 11.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.85% of the company's stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.